Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Profound Medical Corp. T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:PRN)

Fundamentals Snapshot (TSX:PRN)

Opinion & Analysis (TSX:PRN)

VIDEO: Treating Prostate Cancer With Less Side Affects

BTV-Business Television June 21, 2016

VIDEO: A New and Innovative Way to Treat Prostate Cancer

BTV-Business Television June 8, 2016

Bullboard Posts (TSX:PRN)

Q1 2023 Financial Results - Recurring revenue up 43% YOY

..... Summary First Quarter 2023 Results For the quarter ended March 31, 2023, the Company recorded revenue of approximately $1.9...
HomerAndCompany - May 11, 2023

not just one but two articles

By Jayson MacLean Published on May 4, 2023 Last Updated on May 4, 2023 Filed under:   All posts...
Possibleidiot01 - May 4, 2023

JF Tardif

Smart Money: Jean-Franois Tardif on which stocks to target when the market is going sideways Jean-Franois Tardif is laser-focused on...
retiredcf - April 25, 2023

Raymond James - STRONG BUY

 Profound Medical is a Strong Buy, says Raymond James By Jayson MacLean Published on April 11, 2023 ...
Possibleidiot01 - April 11, 2023

Keytruda fails more prostate and lung cancer PhIII trials

ENDPOINTSNEWS Feb 28: Merck's Keytruda fails more prostate trials:
HomerAndCompany - March 17, 2023

On cusp of exponential growth with 5% mo-over-mo rev growth?

2022 ended with 5% month-over-month revenue growth, that the company claims should be maintained or exceeded in 2023. Simple math (5% x...
HomerAndCompany - March 17, 2023